Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GPR88 | Q9GZN0 | 6/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5363282 | 0.98 | PTGER4 (0.53) | PTGER4L3MBTL1GPR88FFAR1PLK1 | |
| SCHEMBL5351093 | 0.95 | PTGER4 (0.54) | PTGER4L3MBTL1GPR88FFAR1PLK1 | |
| SCHEMBL5353711 | 0.91 | PTGER4 (0.54) | PTGER4L3MBTL1GPR88PLK1LMNA | |
| SCHEMBL5346187 | 0.91 | PTGER4 (0.60) | PTGER4L3MBTL1PLK1LMNA | |
| SCHEMBL5352027 | 0.89 | PTGER4 (0.56) | PTGER4L3MBTL1LMNAPPARG | |
| SCHEMBL5351064 | 0.89 | PTGER4 (0.50) | PTGER4L3MBTL1GPR88PLK1PPARG | |
| SCHEMBL5347447 | 0.87 | PTGER4 (0.56) | PTGER4L3MBTL1PLK1 | |
| SCHEMBL6702392 | 0.86 | PTGER4 (0.48) | PTGER4L3MBTL1GPR88PPARG | |
| Hydrochloric Acid SCHEMBL5346242 | 0.86 | PTGER4 (0.47) | PTGER4L3MBTL1GPR88PPARG | |
| SCHEMBL5346137 | 0.85 | PTGER4 (0.50) | PTGER4L3MBTL1GPR88PLK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127487-A1 | Benzoic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-07-01 | — | — | US | claimed |
| US-6710205-B2 | ANTIALLERGENS; ANTICANCER AGENTS; AUTOIMMUNE DISEASES; BONE DISORDERS; RHEUMATIC DISEASES; ANTIULCER AGENTS; SKIN DISORDERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | claimed |
| US-20040002493-A1 | Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-01 | — | — | US | claimed |
| US-20030114435-A1 | Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-06-19 | — | — | US | claimed |
| EP-1314719-A1 | BENZOIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-28 | — | — | EP | claimed |
| EP-1258473-A1 | BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-20 | — | — | EP | claimed |
| US-7196198-B2 | Benzoic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-27 | — | — | US | disclosed |
| US-7196198-B2 | Benzoic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-27 | — | — | US | disclosed |
| US-7196198-B2 | Benzoic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20040127487-A1 | Benzoic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-07-01 | — | — | US | disclosed |
| US-6710205-B2 | ANTIALLERGENS; ANTICANCER AGENTS; AUTOIMMUNE DISEASES; BONE DISORDERS; RHEUMATIC DISEASES; ANTIULCER AGENTS; SKIN DISORDERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20040002493-A1 | Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-01 | — | — | US | disclosed |
| US-20030114435-A1 | Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1314719-A1 | BENZOIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-1258473-A1 | BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002493-A1 | Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient | PTGER1, PTGER4, PTGES | PTGER4 2/4885L3MBTL1 4112/4885GPR88 252/4885 |
| US-20030114435-A1 | Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient | ALOX5, PDGFRB, ALOX15B | PTGER4 71/4885L3MBTL1 1208/4885GPR88 83/4885 |
| US-20040127487-A1 | Benzoic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient | PDGFRB, ALOX5, ALOX15B | PTGER4 114/4885L3MBTL1 1412/4885GPR88 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.